Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Latest Information Update: 24 Nov 2023
At a glance
- Drugs LB 100 (Primary)
- Indications Astrocytoma; Glioblastoma; Gliosarcoma; Oligodendroglioma
- Focus Pharmacokinetics
- 12 Jul 2023 Status changed from recruiting to completed.
- 22 Nov 2021 According to a Lixte Biotechnology Holdings media release, in 2020 enrollment in trial was suspended due to COVID-19 restrictions. Those restrictions have now been lifted and patient recruitment has resumed.
- 23 Oct 2021 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.